Literature DB >> 20717760

A cell-based screen for inhibitors of protein folding and degradation.

Frank Boschelli1, Jennifer M Golas, Roseann Petersen, Vincent Lau, Lei Chen, Diane Tkach, Qiang Zhao, Dave S Fruhling, Hao Liu, Chaneun Nam, Kim T Arndt.   

Abstract

Cancer cells are exposed to external and internal stresses by virtue of their unrestrained growth, hostile microenvironment, and increased mutation rate. These stresses impose a burden on protein folding and degradation pathways and suggest a route for therapeutic intervention in cancer. Proteasome and Hsp90 inhibitors are in clinical trials and a 20S proteasome inhibitor, Velcade, is an approved drug. Other points of intervention in the folding and degradation pathway may therefore be of interest. We describe a simple screen for inhibitors of protein synthesis, folding, and proteasomal degradation pathways in this paper. The molecular chaperone-dependent client v-Src was fused to firefly luciferase and expressed in HCT-116 colorectal tumor cells. Both luciferase and protein tyrosine kinase activity were preserved in cells expressing this fusion construct. Exposing these cells to the Hsp90 inhibitor geldanamycin caused a rapid reduction of luciferase and kinase activities and depletion of detergent-soluble v-Src::luciferase fusion protein. Hsp70 knockdown reduced v-Src::luciferase activity and, when combined with geldanamycin, caused a buildup of v-Src::luciferase and ubiquitinated proteins in a detergent-insoluble fraction. Proteasome inhibitors also decreased luciferase activity and caused a buildup of phosphotyrosine-containing proteins in a detergent-insoluble fraction. Protein synthesis inhibitors also reduced luciferase activity, but had less of an effect on phosphotyrosine levels. In contrast, certain histone deacetylase inhibitors increased luciferase and phosphotyrosine activity. A mass screen led to the identification of Hsp90 inhibitors, ubiquitin pathway inhibitors, inhibitors of Hsp70/Hsp40-mediated refolding, and protein synthesis inhibitors. The largest group of compounds identified in the screen increased luciferase activity, and some of these increase v-Src levels and activity. When used in conjunction with appropriate secondary assays, this screen is a powerful cell-based tool for studying compounds that affect protein synthesis, folding, and degradation.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20717760      PMCID: PMC3024082          DOI: 10.1007/s12192-010-0200-3

Source DB:  PubMed          Journal:  Cell Stress Chaperones        ISSN: 1355-8145            Impact factor:   3.667


  50 in total

1.  Development of a high throughput drug screening assay for the detection of changes in tau levels -- proof of concept with HSP90 inhibitors.

Authors:  Chad A Dickey; Jason Eriksen; Adeela Kamal; Francis Burrows; Srinivas Kasibhatla; Christopher B Eckman; Mike Hutton; Leonard Petrucelli
Journal:  Curr Alzheimer Res       Date:  2005-04       Impact factor: 3.498

2.  Activation of stress-activated MAP protein kinases up-regulates expression of transgenes driven by the cytomegalovirus immediate/early promoter.

Authors:  W Bruening; B Giasson; W Mushynski; H D Durham
Journal:  Nucleic Acids Res       Date:  1998-01-15       Impact factor: 16.971

3.  Cdc37 is a molecular chaperone with specific functions in signal transduction.

Authors:  Y Kimura; S L Rutherford; Y Miyata; I Yahara; B C Freeman; L Yue; R I Morimoto; S Lindquist
Journal:  Genes Dev       Date:  1997-07-15       Impact factor: 11.361

4.  CDC37 is required for p60v-src activity in yeast.

Authors:  B Dey; J J Lightbody; F Boschelli
Journal:  Mol Biol Cell       Date:  1996-09       Impact factor: 4.138

5.  Proteasome inhibitors: a novel class of potent and effective antitumor agents.

Authors:  J Adams; V J Palombella; E A Sausville; J Johnson; A Destree; D D Lazarus; J Maas; C S Pien; S Prakash; P J Elliott
Journal:  Cancer Res       Date:  1999-06-01       Impact factor: 12.701

6.  The Ydj1 molecular chaperone facilitates formation of active p60v-src in yeast.

Authors:  B Dey; A J Caplan; F Boschelli
Journal:  Mol Biol Cell       Date:  1996-01       Impact factor: 4.138

7.  Reactivation of silenced, virally transduced genes by inhibitors of histone deacetylase.

Authors:  W Y Chen; E C Bailey; S L McCune; J Y Dong; T M Townes
Journal:  Proc Natl Acad Sci U S A       Date:  1997-05-27       Impact factor: 11.205

8.  A novel chaperone-activity-reducing mechanism of the 90-kDa molecular chaperone HSP90.

Authors:  H Itoh; M Ogura; A Komatsuda; H Wakui; A B Miura; Y Tashima
Journal:  Biochem J       Date:  1999-11-01       Impact factor: 3.857

Review 9.  Hsp90 inhibitor geldanamycin and its derivatives as novel cancer chemotherapeutic agents.

Authors:  Y Miyata
Journal:  Curr Pharm Des       Date:  2005       Impact factor: 3.116

10.  HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor.

Authors:  Jeffrey J Kovacs; Patrick J M Murphy; Stéphanie Gaillard; Xuan Zhao; June-Tai Wu; Christopher V Nicchitta; Minoru Yoshida; David O Toft; William B Pratt; Tso-Pang Yao
Journal:  Mol Cell       Date:  2005-05-27       Impact factor: 17.970

View more
  1 in total

1.  Metabolic stress controls mutant p53 R248Q stability in acute myeloid leukemia cells.

Authors:  Nerea Allende-Vega; Martin Villalba
Journal:  Sci Rep       Date:  2019-04-04       Impact factor: 4.379

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.